Pancreatic ductal carcinomas and lung adenocarcinomas are aggressive and deadly cancers, among which rare tumors harbor NRG1 fusions making the NRG1-rearranged tumor candidates suitable for specific targeted therapies. Here, NRG1 is linked to lung adenocarcinoma.